· Published by Health Canada · Official notice
This is duplicated text of a letter from Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
December 20, 2010
Subject: Pfizer Initiates Product Withdrawal of THELIN® (sitaxsentan sodium) Worldwide
Pfizer Canada, in collaboration with Health Canada, has decided to voluntarily withdraw THELIN® (sitaxsentan sodium) tablets from the Canadian market due to concerns of liver damage. THELIN® is an oral medication used in the treatment of pulmonary arterial hypertension (PAH).
While liver damage is a known complication of THELIN® therapy, Pfizer recently became aware of new safety information that led the company to conclude that the benefit of this medicine no longer outweighs the risk for the general population of patients with PAH. Because this potentially life-threatening liver injury is unpredictable, and given the availability of other treatment options for PAH, Pfizer decided to remove THELIN® from the market.
In the interest of patient safety, Pfizer will be discontinuing availability of THELIN® in all countries where it is approved. Pfizer will also be discontinuing all clinical studies of THELIN®.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving THELIN® should be reported to Pfizer Canada or Health Canada at the following addresses:
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, QC H9J 2M5
Telephone: 1-800-463-6001
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
For medical or pharmaceutical requests please contact Pfizer Canada Inc's Medical Information Department at 1-800-463-6001.
Sincerely,
original signed by
Bernard Prigent, MD, MBA
Vice-President and Medical Director
Pfizer Canada Inc.